Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q3 2018 Earnings Presentation
11 slides from Anika Therapeutics's earnings presentation, Oct 24, 2018
Slide 1: Third Quarter 2018 Earnings Call Presentation
Third Quarter 2018 Earnings Call Presentation October 24, 2018 NASDAQ: ANIK 0
Slide 2: Safe Harbor Statement
Safe Harbor Statement The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate mi
Slide 3: Foundation for Long-Term Growth
Foundation for Long-Term Growth People Pipeline Profitability 2
Slide 4: Expanding Leadership Team & Board of Directors
Expanding Leadership Team & Board of Directors VP of International Sales: Evaluate and improve international (OUS) business VP of Operations: Drive operational efficiency Independent Directors: Added Cheryl Blanchard, Ph.D. and Susan Vogt to Board of Directors, reinforcing Anika’s commitment to the
Slide 5: Committed to CINGAL U.S. Approval
Committed to CINGAL U.S. Approval Pursuing multiple strategies for pathway forward Compiling and evaluating totality of extensive pivotal data, along with real-world evidence from physicians in Canada and Europe Plan to meet with the FDA in Q1 2019 4
Slide 6: Growing Portfolio of Regenerative Treatments
Growing Portfolio of Regenerative Treatments BONE REPAIR THERAPY Received 510(k) clearance in Q4 2017 Commercial launch expected in 2H 2019 Plan to utilize hybrid commercial model U.S. market opportunity of $250-300M annually ROTATOR CUFF REGENERATIVE THERAPY Product prototype development underway U
Slide 7: Advancing ORTHOVISC-T for U.S. Approval
Advancing ORTHOVISC-T for U.S. Approval Currently indicated in the E.U. to relieve pain and restore function in tendons affected by chronic lateral epicondylosis, or “tennis elbow” Post-market study in Europe to commence in the coming months Phase III trial to initiate in 2019 for U.S. approval Pote
Slide 8: Q3 2018 Financial Highlights
Q3 2018 Financial Highlights Total Revenue Diluted EPS Product Gross Margin Operating Cash Flow (Millions) (Millions) $0.53 $26.8 $27.2 $0.46 77% $34 69% $25 *$149M Cash & Investments as of 9/30/2018; No Debt Q3 2018 Q3 2017 Q3 2018 Q3 2017 Q3 2018 Q3 2017 YTD 9/30/2018 YTD 9/30/2017 • CINGAL intern
Slide 9: Multiple Near-Term Revenue Growth Drivers
Multiple Near-Term Revenue Growth Drivers Strengthening International distribution network Resuming shipment of voluntarily recalled HYAFF-based products in Q4 2018 International expansion of CINGAL U.S. launch of Bone Repair therapy expected in 2H 2019 Strategic partnerships and “tuck-in” acquisiti
Slide 10: Building a Fully-Integrated Commercial Company
Building a Fully-Integrated Commercial Company: Hybrid Commercial Model Seeking partner with established surgical orthopedics sales force Small in-house team of highly-skilled clinical marketing specialists Greater control over market access, sales and marketing, and pricing More rapid market penetr
Slide 11: Q&A
Q&A Third Quarter 2018 Earnings Call Presentation October 24, 2018 NASDAQ: ANIK 10